MedTrace Logo

CD133+ Cell Therapy for Refractory Coronary Heart Disease

NCT01049867 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-01-15

No results posted yet for this study

Summary

The aim of this study is to evaluate if the intracoronary infusion of autologous bone-marrow derived CD133+ endothelial precursor cells is able to promote neovascularization and to improve myocardial perfusion and contractility in patients with refractory coronary heart disease, characterized by poor response to standard coronary interventions, severe impairment of the quality of life, and poor prognosis.

Conditions

Interventions

PROCEDURE

Intracoronary Infusion of CD133+ Cells

Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.

Sponsors & Collaborators

  • Hospital y Clinica OCA, S.A. de C.V.

    lead OTHER

Principal Investigators

  • Augusto Rojas-Martinez, M.D./D.Sc. · Director, Cell Therapy Laboratory. OCA Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-12-31
Completion
2011-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049867 on ClinicalTrials.gov